Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Eli Lilly escalated its war on the GLP-1 compounding ecosystem Thursday with a public safety warning that could permanently reshape the regulatory landscape: tirzepatide mixed
Thursday’s headlines underscore a biotech sector caught between transformative clinical milestones and escalating operational risks. BridgeBio delivered highly anticipated Phase 3 FORTIFY data for its
The FDA has set a radical regulatory precedent for ultra-rare diseases by approving leucovorin for a specific cerebral folate deficiency (CFD) subset without a clinical
Today delivered a rare alignment of clinical, regulatory, and scientific milestones. Xenon’s azetukalner posted the highest placebo-adjusted seizure reduction ever seen in a pivotal epilepsy
The 2026 MDA Clinical & Scientific Conference kicks off today in Orlando, serving as the first real-world test of the Makary-era regulatory posture on gene
Johnson & Johnson’s teclistamab combination secured a record-breaking 55-day FDA approval under the Commissioner’s National Priority Voucher pilot, setting a new benchmark for accelerated hematology
Manufacturing and regulatory milestones anchor today’s action. Vericel’s FDA approval for its new cell therapy facility positions MACI for international expansion, while Glenmark secures 180-day
Non-dilutive financing is redefining late-stage development economics. Teva’s $400 million Blackstone deal for duvakitug and Royalty Pharma’s APAC expansion signal that asset-specific capital—not balance-sheet debt—is
The FDA drew a hard line on gene therapy Monday, fully liberating Intellia’s CRISPR pipeline from clinical holds while simultaneously enforcing a rigorous Phase 3
Last week was defined by regulatory milestones and market reality checks. The FDA approved Ascendis Pharma’s YUVIWEL (navepegritide) on Friday, the second achondroplasia therapy and
